142 related articles for article (PubMed ID: 18774008)
1. Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers.
Price MJ; Teirstein PS
Am J Cardiol; 2008 Sep; 102(6):790-5. PubMed ID: 18774008
[TBL] [Abstract][Full Text] [Related]
2. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers.
Price MJ; Coleman JL; Steinhubl SR; Wong GB; Cannon CP; Teirstein PS
Am J Cardiol; 2006 Sep; 98(5):681-4. PubMed ID: 16923461
[TBL] [Abstract][Full Text] [Related]
3. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
[TBL] [Abstract][Full Text] [Related]
4. Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition.
Lordkipanidzé M; Pharand C; Nguyen TA; Schampaert E; Diodati JG
Ther Drug Monit; 2008 Jun; 30(3):372-8. PubMed ID: 18520610
[TBL] [Abstract][Full Text] [Related]
5. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
Jakubowski JA; Payne CD; Li YG; Brandt JT; Small DS; Farid NA; Salazar DE; Winters KJ
Thromb Haemost; 2008 Feb; 99(2):409-15. PubMed ID: 18278193
[TBL] [Abstract][Full Text] [Related]
6. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects.
Savcic M; Hauert J; Bachmann F; Wyld PJ; Geudelin B; Cariou R
Semin Thromb Hemost; 1999; 25 Suppl 2():15-9. PubMed ID: 10440417
[TBL] [Abstract][Full Text] [Related]
7. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
Patti G; Nusca A; Mangiacapra F; Gatto L; D'Ambrosio A; Di Sciascio G
J Am Coll Cardiol; 2008 Sep; 52(14):1128-33. PubMed ID: 18804738
[TBL] [Abstract][Full Text] [Related]
8. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study.
Collet JP; Silvain J; Landivier A; Tanguy ML; Cayla G; Bellemain A; Vignolles N; Gallier S; Beygui F; Pena A; Montalescot G
Circulation; 2008 Sep; 118(12):1225-33. PubMed ID: 18765393
[TBL] [Abstract][Full Text] [Related]
9. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status.
Weerakkody GJ; Jakubowski JA; Brandt JT; Farid NA; Payne CD; Zhu J; Warner MR; Naganuma H; Winters KJ
Am J Cardiol; 2007 Jul; 100(2):331-6. PubMed ID: 17631093
[TBL] [Abstract][Full Text] [Related]
10. Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease.
Lev EI; Arikan ME; Vaduganathan M; Alviar CL; Tellez A; Mathuria N; Builes A; Granada JF; del Conde I; Kleiman NS
Am Heart J; 2007 Oct; 154(4):694.e1-7. PubMed ID: 17892993
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Storey RF; Angiolillo DJ; Patil SB; Desai B; Ecob R; Husted S; Emanuelsson H; Cannon CP; Becker RC; Wallentin L
J Am Coll Cardiol; 2010 Oct; 56(18):1456-62. PubMed ID: 20832963
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
[TBL] [Abstract][Full Text] [Related]
13. Platelet function after cessation of chronic clopidogrel therapy.
Perakis PG; Yunus T; Long G; Cheema ZF; Hammond R; Shanley CJ
Am Surg; 2012 Jan; 78(1):51-6. PubMed ID: 22273313
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
[TBL] [Abstract][Full Text] [Related]
15. Single-dose pharmacodynamics of clopidogrel.
Thebault JJ; Kieffer G; Cariou R
Semin Thromb Hemost; 1999; 25 Suppl 2():3-8. PubMed ID: 10440415
[TBL] [Abstract][Full Text] [Related]
16. A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel.
Bernlochner I; Morath T; Brown PB; Zhou C; Baker BA; Gupta N; Jakubowski JA; Winters KJ; Schömig A; Kastrati A; Sibbing D
Platelets; 2013; 24(1):15-25. PubMed ID: 22372531
[TBL] [Abstract][Full Text] [Related]
17. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Price MJ; Angiolillo DJ; Teirstein PS; Lillie E; Manoukian SV; Berger PB; Tanguay JF; Cannon CP; Topol EJ
Circulation; 2011 Sep; 124(10):1132-7. PubMed ID: 21875913
[TBL] [Abstract][Full Text] [Related]
18. Inter-individual variability in response to clopidogrel in patients with coronary artery disease.
Dziewierz A; Dudek D; Heba G; Rakowski T; Mielecki W; Dubiel JS
Kardiol Pol; 2005 Feb; 62(2):108-17; discussion 118. PubMed ID: 15815794
[TBL] [Abstract][Full Text] [Related]
19. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment.
Angiolillo DJ; Costa MA; Shoemaker SB; Desai B; Bernardo E; Suzuki Y; Charlton RK; Zenni MM; Guzman LA; Bass TA
Am J Cardiol; 2008 Feb; 101(4):440-5. PubMed ID: 18312754
[TBL] [Abstract][Full Text] [Related]
20. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]